Paloma Partners’s Vivani Medical VANI Stock Holding History

Paloma Partners’s Portfolio VANI Stock Details VANI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-22,469	Closed	-$215K	–	2125
2021 Q3	$215K	Sell	22,469 -23,891	-52%	-$269K	0.01%	830
2021 Q2	$687K	Buy	+46,360	New	+$896K	0.01%	830
2017 Q3	–	Sell	-2,977	Closed	-$90K	–	2452
2017 Q2	$90K	Buy	+2,977	New	+$84.2K	﹤0.01%	2083

Other funds holding VANI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Paloma Partners's VANI Position: Q4 2021 in Review

Paloma Partners sold out of Vivani Medical (VANI) in Q4 2021, closing a stake of 22,469 shares — an estimated $215K sold.

Paloma Partners first reported a position in VANI in Q2 2017 and held it in 3 quarters. The position peaked at $687K in Q2 2021. 30 funds tracked by Wall St. Rank hold VANI as of Q4 2021.

Paloma Partners reported no remaining Vivani Medical position as of Q4 2021 after selling out during the quarter.
Paloma Partners sold 22,469 Vivani Medical shares in Q4 2021, an estimated $215K.
Paloma Partners first reported a position in Vivani Medical in Q2 2017 and held it in 3 quarters.
Paloma Partners's Vivani Medical position peaked at $687K in Q2 2021.
30 funds tracked by Wall St. Rank held Vivani Medical as of Q4 2021.

Based on Paloma Partners's 13F filing for Q4 2021, filed 14 Feb 2022.